Related Experiment Video
Updated: May 27, 2026
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports
Chun-Geun Ryu1, Eun-Joo Jung, Gangmi Kim
1Department of Surgery, Colorectal Cancer Center, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
Journal of the Korean Society of Coloproctology
|November 22, 2011
Summary
The FOLFOX chemotherapy regimen for colorectal cancer can rarely cause severe lung problems like pulmonary fibrosis. This study reports two such cases and highlights the need for managing this rare side effect.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- The FOLFOX regimen (Oxaliplatin, 5-fluorouracil, leucovorin) is a standard chemotherapy for colorectal cancer.
- Common side effects like neutropenia and neuropathy are generally manageable.
- Pulmonary toxicity is a rare but serious adverse event associated with FOLFOX.
Observation:
- Two patients with colorectal carcinoma developed rapidly progressing pulmonary fibrosis.
- These cases occurred during treatment with the FOLFOX regimen.
- No established guidelines exist for managing FOLFOX-induced pulmonary toxicity.
Findings:
- Oxaliplatin-based chemotherapy can lead to severe pulmonary complications.
- Rapidly developing pulmonary fibrosis is a rare but significant toxicity of the FOLFOX regimen.
- Early recognition and management strategies are crucial for patients experiencing pulmonary symptoms.
Implications:
- This study underscores the importance of monitoring for pulmonary toxicity in colorectal cancer patients receiving FOLFOX.
- Further research is needed to establish guidelines for the management of this rare adverse event.
- Clinicians should consider pulmonary fibrosis in the differential diagnosis of respiratory symptoms in patients on FOLFOX therapy.
Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:27Pneumothorax-II
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations: